Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.

Jie LiuShuo YangBihui CaoGuangyu ZhouFengjuan ZhangYuan WangRixin WangLipeng ZhuYa MengCong HuHui LiangXu LinKangshun ZhuGuokai ChenKathy Qian LuoLijun DiQi Zhao

Published in: Journal of hematology & oncology (2021)

Together, our results suggest that B7-H3 may serve as a target for NSCLC therapy and support the further development of two therapeutic agents in the preclinical and clinical studies.

Keyphrases

cell therapy
small cell lung cancer
single cell
peripheral blood
cancer therapy
advanced non small cell lung cancer
stem cells
brain metastases
drug delivery
bone marrow
smoking cessation